Kuros Biosciences AG
Swiss ExchangeTotal Valuation
Kuros Biosciences AG carries a market capitalization of 761.58M, placing it among publicly traded companies globally. Its enterprise value stands at 61.81M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 761.58M |
| Enterprise Value | 61.81M |
Share Statistics
Kuros Biosciences AG currently has 351,157.00 shares outstanding.
| Shares Outstanding | 351,157.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 74.19, and the price-to-book ratio stands at -0.28.
| PE Ratio | N/A |
| PS Ratio | 74.19 |
| PB Ratio | -0.28 |
| P/TBV Ratio | 17.54 |
| P/FCF Ratio | -3.87 |
| P/OCF Ratio | -3.87 |
Enterprise Valuation
| EV / Sales | 61.81 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Kuros Biosciences AG maintains a current ratio of 6.94, meaning it holds 6.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 649.34, indicating elevated leverage, while an interest coverage ratio of -2.96 demonstrates limited ability to service its debt obligations.
| Current Ratio | 6.94 |
| Quick Ratio | 6.86 |
| Debt / Equity | 649.34 |
| Debt / EBITDA | -1.18 |
| Interest Coverage | -2.96 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -86.96 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Kuros Biosciences AG's stock has declined approximately -32.85814% over the past 52 weeks. The 50-day moving average sits at 20.10, while the 200-day moving average is 25.26.
| Beta (5Y) | N/A |
| 52-Week Price Change | -32.85814% |
| 50-Day Moving Average | 20.10 |
| 200-Day Moving Average | 25.26 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Kuros Biosciences AG generated 1.00M in revenue and converted that into -30.82M in net income, yielding earnings per share of -111.10. EBITDA reached -23.27M, while operating income came in at -23.27M.
| Revenue | 1.00M |
| Gross Profit | -11.95M |
| Operating Income | -23.27M |
| Pretax Income | -30.82M |
| Net Income | -30.82M |
| EBITDA | -23.27M |
| EBIT | -23.27M |
| Earnings Per Share (EPS) | -111.10 |
Balance Sheet
Kuros Biosciences AG holds 39.85M in cash and equivalents against 27.47M in total debt, resulting in a net debt position of -12.38M. Total book value stands at -267.81M, with working capital of 34.53M providing operational flexibility.
| Cash & Cash Equivalents | 39.85M |
| Total Debt | 27.47M |
| Net Debt | -12.38M |
| Equity (Book Value) | -267.81M |
| Book Value Per Share | -965.22 |
| Working Capital | 34.53M |
Cash Flow
Kuros Biosciences AG produced -19.17M in operating cash flow over the past twelve months.
| Operating Cash Flow | -19.17M |
| Capital Expenditures | N/A |
| Free Cash Flow | -19.17M |
| FCF Per Share | -69.09 |
Margins
Kuros Biosciences AG operates with a gross margin of -1,194.90, reflecting its pricing power and cost economics. The operating margin of -2,326.60 and net profit margin of -3,082.50 provide insight into operational efficiency.
| Gross Margin | -1,194.90 |
| Operating Margin | -2,326.60 |
| Pretax Margin | -3,082.50 |
| Profit Margin | -3,082.50 |
| EBITDA Margin | -2,326.60 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -40.61 |
| FCF Yield | -25.84 |
Stock Splits
Kuros Biosciences AG's most recent stock split took place on October 8, 2020 with a 200:217 split ratio.
| Last Split Date | 10/8/2020 |
| Split Ratio | 200:217 |
Scores
Kuros Biosciences AG posts an Altman Z-Score of -8.98, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -8.98 |